Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
Authors:
- Shakira DawoodSDShakira Dawood
- Brigid McMillanBMBrigid McMillan
- Karryn BrownKBKarryn Brown
- David RichardsonDRDavid Richardson
- Kudakwashe SimbaKSKudakwashe Simba
- Lillian F. AnderaLALillian F. Andera
- Jessica OpieJOJessica Opie
- Katherine AntelKAKatherine Antel
- Stuart MoreSMStuart More
- Ayesha AllieAAAyesha Allie
- Zainab MohamedZMZainab Mohamed
Open Access
- 25 November 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1813
Abstract
Background: Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking. Method: This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography / computed tomography (PET/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed. Results: The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%, P = 0.599) as was 5-year PFS (83% vs. 88%, P = 0.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients ( P = 0.684), and PFS was 100% and 82%, respectively ( P = 0.086). Conclusions: This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.Keywords
Funding Information
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health (D43 TW010345)
- Bristol Myers Squibb Foundation
- the BLOODSA Foundation
- Cancer Association of South Africa
- South African Medical Research Council
This publication has 39 references indexed in Scilit:
- Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort studyeClinicalMedicine, 2024
- Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040International Journal of Cancer, 2022
- Treating early‐stage Hodgkin lymphoma in resource‐limited settings: InPOG‐HL‐15‐01 experiencePediatric Blood & Cancer, 2021
- Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group GuidelinesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2020
- Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltrationAnnals of Hematology, 2018
- Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: First report by the South African Children's Cancer Study GroupPediatric Blood & Cancer, 2017
- Improved survival time trends in Hodgkin's lymphomaCancer Medicine, 2016
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Prognostic significance of the number of involved areas in the early stages of Hodgkin's diseaseCancer, 1984